Transport research of breviscapine across Caco-2 monolayer model using two assay methods

Chinese Pharmacological Bulletin

Volumn 25, Issue 6, 2009, Pages 831-833

  Qi, Yun ^a   Wang, Min ^a   Cai, Run Ian ^a   Xie, Chen ^a   Wang, Xiang Yan ^a   Li, Xiao Hong ^a  

^a INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

Author keywords

Apparent permeability coefficient (Papp); Bidirection transport; Breviscapine; Caco 2 cell monolayer model

Indexed keywords

BREVISCAPINE; DIMETHYL SULFOXIDE; SCUTELLAREIN;

ARTICLE; CELL STRAIN CACO 2; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL;

EID: 68849089480     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. + -ATPase activity of proximal tubule in early diabetic rats [J]. Chin Pharmacol Bull, 2007, 23(7):917-920 (Pubitemid 47555795)
2. Chai W S, Zhai S P, Wu S L, Chen B Y. The effect of breviscapine on pulmonary fibrosis induced by bleomycin in rats[J]. Chin Pharmacol Bull, 2008, 24(1):113-116 (Pubitemid 351587360)
3. Du G J, Lin HH, Xu Q T. Breviscapine promotes K562 cell apoptosis induced by doxorubicin [J]. Chin Pharmacol Bull, 2007, 23(8):1043-1047
4. Ding J S, Zhang J S. Absorption of breviscapine in small intestine of rat [J]. J China Pharm Uni, 2003, 34(1):65-69 (Pubitemid 43046407)
5. Ge Q H, Zhou Z, Zhi X J, et al. Pharmacokinetics and absolute bioavailability of breviscapine in beagle dogs [J]. Chin J Pharm, 2003, 34(12):618-20,32.
6. Mou Y P, Wu G, Zhou L S, He Y L. Application of Caco-2 cell model in drug research [J]. Chin Pharmacol Bull, 2005, 21(5): 536-539 (Pubitemid 41113083)
7. Wang M, Qi Y. Recent progress in caco-2 cell model and Its application in drug absorption [J]. Chin Pham J, 2007 ,42(16): 1201-1204
8. Cai R L, Wang M, Qi Y, et al. Selection and utilization on the evaluation criterions of caco-2 cell model [J]. Chin Pham J, 2008, 43(24):1871-1875
9. Benzie I F, Strain J J. The ferric reducing ability of plasma ( FRAP) as a measure of "antioxidant power" ; the FRAP assay [J]. Anal Biochem, 1996, 239:70-76
10. Polli J W, Wring S A, Humphreys J E, et al. Rational use of in vitro P-glycoprotein assays in drug discovery[J]. J Pharmacol. Exp Ther, 2001, 299(1):620-628
11. Yee S Y. In vitro permeability across Caco-2 cell (colonic) can predict in vivo ( small intestinal ) absorption in man-fact or myth [J]. Pharm Res, 1997, 14(6):763-766
12. Wang M, Xie C, Cai R L, et al. Studies on antioxidant activities of breviscapine in the cell-free system[J]. Am J Chin Med, 2008, 36(6):1199-1207
13. Konsoula R, Barile F A. Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 Cells[J]. Toxicol In Vitro, 2005, 19(5):675-684 (Pubitemid 40719542)
14. Konsoula R, Barile F A. Correlation of in vitro cytotoxicity with paracellular permeability in mortal rat intestinal cells[J]. J Pharmacol Toxicol Methods, 2007, 55(2):176-183 (Pubitemid 46237745)